The rationale for using MEM as a symptomatic treatment for advanced AD patients, but not as a disease-modifying early treatment, is in line with the previous judgment that NMDAR abnormalities are merely a consequence of Aβ/tau pathology. Here, MAPT is linked to Alzheimer disease.